Bayer Wins FDA Fast-Track for Lynkuet While Decarbonizing Aspirin Production in Spain
Published on 10/02/2026 at 12:01 | Editorial boerse-global.de
Bayer's pharmaceutical pipeline has picked up regulatory speed in the United States just as the company presses ahead with an industrial overhaul in Europe. The FDA has granted priority review status to the German group's marketing application for Lynkuet, whose active ingredient elinzanetant targets moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone-receptor-positive breast cancer.
The accelerated pathway shortens the standard review window considerably, potentially opening the door to a faster commercial launch in the lucrative US healthcare market. For Bayer's pharma division, the decision represents a meaningful operational waypoint. With patents on established blockbusters expiring, the company faces pressure to shepherd new revenue drivers through late-stage clinical development and into the market without delay.
Portfolio Reshaping and Fresh Capital
The regulatory progress fits into a broader sequence of moves through which management is sharpening the group's profile. In oncology, Bayer is parting with older rights: the cancer drug Stivarga is being sold to Aachen-based pharmaceutical company Grünenthal for up to EUR 375 million. The transaction is expected to close at the end of 2026 or in early 2027.
At the same time, Bayer is advancing biological crop-protection solutions through its in-house investment arm Leaps by Bayer, which led a financing round at biotech firm Robigo. Separately, the group secured additional liquidity on the capital market, raising a total of EUR 2 billion through the placement of two hybrid bonds, each with a 30-year maturity. The two tranches carry non-call periods of six and nine years respectively. According to the company, the proceeds are earmarked for general corporate purposes, bringing the total outstanding volume of hybrid bonds to EUR 6.55 billion.
A Carbon-Free Aspirin Plant in Asturias
On the industrial side, Bayer is pushing the sustainable conversion of its manufacturing base. For decarbonizing active-ingredient production for the painkiller Aspirin at its Spanish site in Langreo, the company this week received an award as part of energy supplier Iberdrola's Convive prizes. Bayer is investing EUR 17 million in the Asturian facility. The new energy system is entering test operation and is scheduled to begin regular production before the end of 2026.
Should investors sell immediately? Or is it worth buying Bayer?
According to the company, the site will become the first fully decarbonized pharmaceutical production facility in Spain, avoiding more than 6,500 tonnes of carbon dioxide annually. Process-related emissions from manufacturing the long-established medicine will thereby fall to nearly zero. Bayer regards the plant as one of the first decarbonized production sites in the pharmaceutical industry across Europe. The project is intended to keep the location competitive over the long term and prepare it for stricter environmental rules.
Consumer Health and External Innovation
Beyond the European modernization work, Bayer is driving its over-the-counter business forward. In the United States, the company launched MiraSOFT, a stool softener based on the active ingredient docusate sodium. The product is sold exclusively through the CVS Pharmacy chain and is available in more than 7,000 of its stores as well as via the associated online channel.
Management is also hunting for fresh momentum in its own drug development. Under a showcase organized by the Bayer Co.Lab initiative, Asian biotech companies presented their RNA technologies at a specialist conference in Boston. Representatives from Bayer's business development and licensing units explored opportunities for joint projects and partnerships on site.
Shares Under Pressure
Despite these operational steps, the stock came under noticeable selling pressure in the financial markets. Yesterday the share lost 5.1 percent and closed at EUR 45.31. A cautious assessment from JPMorgan contributed to the souring mood. Analyst Richard Vosser judged early consensus estimates for the third quarter to be probably too high.
Additional caution was triggered yesterday by the legal disputes in the United States. In a new case concerning the Roundup complex in the US state of Missouri, plaintiffs once again questioned the safety and product design of the herbicide while a verdict was pending. The persistent legal risks thus overshadowed the operational progress and clouded the picture for investors.
The stock currently trades at EUR 45.18, giving it a gain of 22 percent since the start of the year. Investors are looking to the next set of business figures for clarity on near-term fundamental development. Bayer has scheduled the release of third-quarter 2026 results, along with an accompanying video call for investors, for November 3. Market observers are likely to use that date above all to analyze the course of business in the agricultural division and the progress of the pharmaceutical unit's realignment in detail.
Ad
Bayer Stock: New Analysis - 2 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
